Cyclopamine

目录号:S1146 别名: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine是一种特异性Hedgehog (Hh)信号通路拮抗剂,作用于Smoothened (Smo),在TM3Hh12细胞中IC50为46 nM。

规格 价格 库存 购买数量  
RMB 1227.56 现货
RMB 2188.93 现货
RMB 3037.37 现货
RMB 3833.48 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的5个实验数据:

  • (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

    (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

  • Immuofluorescence staining of Gli-1 in MHCC97H cells under normal control or 100 ng/ml CCL2 stimulation or 10 µM Cyc combined with 100 ng/ml CCL2 stimulation for 48 h. Red represents Gli-1 staining. Blue represents nuclear DNA staining by DAPI. Cyc, cyclopamine; CCL2, chemokine (C-C motif) ligand 2.

    Oncol Rep, 2018, 39(1):21-30. Cyclopamine purchased from Selleck.

    (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

  • For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

产品描述 Cyclopamine是一种特异性Hedgehog (Hh)信号通路拮抗剂,作用于Smoothened (Smo),在TM3Hh12细胞中IC50为46 nM。
靶点
Smoothened [1]
(TM3Hh12 cells)
46 nM
体外研究

Cyclopamine 抑制Hedgehog信号通路, IC50 为46 nM, 且在[3H]Hh-Ag结合实验中,作用于CHO-K1细胞,抑制人类Smo受体活性,IC50为 280 nM。[1] Cyclopamine作用于表达Patched (PTCH) mRNA的肠源性肿瘤细胞,显著抑制 Hedgehog通路活性,这种作用存在剂量依赖性,且浓度为3 μM时,抑制肿瘤细胞生长,抑制达75-95%, 但是作用于不表达PTCH mRNA的结肠癌细胞没有效果,说明Cyclopamine 特定作用于Hedgehog 通路,且没有毒性。[2]通过与Smo直接作用而抑制Hedgehog信号,Cyclopamine (10 μM) 抑制SMOhigh Cyclopamine-反应细胞系L3.6sl和 Panc 05.04增殖,抑制达 75-80%,且使凋亡率提高2.5到 3.5倍,但是不影响BxPC3-SMOlow 细胞系。[3] Cyclopamine 处理E3LZ10.7细胞系,显著降低Snail mRNA,且提供E-钙粘着蛋白转录。Cyclopamine处理Hedgehog依赖型 L3.6pl 细胞,显著抑制浸润型细胞, 使转移细胞降低500多倍,但是对Hedgehog非依赖性细胞系Panc-1没有影响。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 NYTqcHBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTVwOE[2OkDPxE1? NUj3SplLW0GQR1XS
DOHH-2 M4WwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFe1VHJKSzVyPUmuN|U3QDlizszN NHTKWHdUSU6JRWK=
no-10 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Ht[mlEPTB;OT65NFM6KM7:TR?= MkG2V2FPT0WU
LS-513 NVWyTGlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7TTWM2OD1zMT6zOVQ4KM7:TR?= MnnxV2FPT0WU
ALL-PO NYfrWoE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnvTWM2OD1zMT63O|M1KM7:TR?= Mn3hV2FPT0WU
8-MG-BA MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rISGlEPTB;MUOuNVEzOyEQvF2= NID4RZZUSU6JRWK=
RPMI-8402 Mkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTF3Lki1N|ch|ryP NIDVcVlUSU6JRWK=
EoL-1-cell MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzLTWM2OD1zOD61PVQ5KM7:TR?= MkHEV2FPT0WU
NALM-6 M3Pv[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF7LkCxOlch|ryP NULOT2hHW0GQR1XS
DEL NH21dFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\uTWM2OD1{MD6xOFcyKM7:TR?= MVnTRW5ITVJ?
SR NFKyR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTtTWM2OD1{Mz62O|E2KM7:TR?= NIPQN3lUSU6JRWK=
697 MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHlXmJKSzVyPUK2MlYyPTVizszN NGnjfHdUSU6JRWK=
COLO-829 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvxTZU2UUN3ME2yOk45PDh|IN88US=> M1n6TXNCVkeHUh?=
EVSA-T NXfWUJVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjLN3hHUUN3ME2yO{42PTZzIN88US=> Ml3zV2FPT0WU
ATN-1 NIWzbmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTNzLkKzNlkh|ryP NWLsPHM3W0GQR1XS
L-363 M4T0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1mzPWlEPTB;M{GuO|Q3OSEQvF2= M3vSWXNCVkeHUh?=
LAMA-84 NIrFXYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDBfI9KSzVyPUOyMlUzOTFizszN M{LnTHNCVkeHUh?=
NOS-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPWTWM2OD1|ND6yPVU3KM7:TR?= MnvyV2FPT0WU
BB30-HNC NHf5PZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTN2LkOzNFYh|ryP NFLlO3NUSU6JRWK=
BC-1 NXHL[GZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PIUWlEPTB;M{euPVc1PiEQvF2= M4LYUXNCVkeHUh?=
IST-SL2 NYPoPZZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGOyXFdKSzVyPUO4MlIzPCEQvF2= M3rVR3NCVkeHUh?=
D-392MG M{W4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{O3TGlEPTB;NECuNlIyPSEQvF2= NYXGSZJyW0GQR1XS
no-11 MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\DXlZKSzVyPUSwMlU2OjFizszN Mk[zV2FPT0WU
LC4-1 NX;uRlRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XUN2lEPTB;NECuPFcyPiEQvF2= NWG5O2hyW0GQR1XS
A388 NH3v[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnSZWZKSzVyPUSyMlU5PDhizszN MoPMV2FPT0WU
NTERA-S-cl-D1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTR{LkewO|Qh|ryP NEPDWpZUSU6JRWK=
CESS M3\3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnIVpk1UUN3ME20OE4zOjN{IN88US=> M{X6RnNCVkeHUh?=
RS4-11 Mn7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TJ[mlEPTB;NEmuNFk{QCEQvF2= NFjiPWdUSU6JRWK=
MS-1 NVO0OWF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnNe5JKSzVyPUWwMlk{PTFizszN NELmOm9USU6JRWK=
CTV-1 Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnQbWJKSzVyPUWxMlA4PCEQvF2= M2DxWHNCVkeHUh?=
D-502MG M1\KNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLicoFKSzVyPUWxMlYzPzFizszN NIDqcndUSU6JRWK=
ML-2 NGr0fXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTV{LkmxPVUh|ryP MX;TRW5ITVJ?
SK-NEP-1 NYLqSnFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfLTWM2OD13Mz6zPVI{KM7:TR?= MnrDV2FPT0WU
LOXIMVI M{XmPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37xb2lEPTB;NUOuOVg5PCEQvF2= NFjnfFlUSU6JRWK=
DJM-1 M4\qfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HtO2lEPTB;NU[uN|M6OSEQvF2= NIrTPXZUSU6JRWK=
GI-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTV4Lk[xOFkh|ryP MlzMV2FPT0WU
IST-MES1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz3TWM2OD14MD61OFk{KM7:TR?= NEHTNVRUSU6JRWK=
MV-4-11 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTZyLk[1N|gh|ryP MmqxV2FPT0WU
OVCAR-4 NXnqSoQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzGXpo4UUN3ME22N{42PjV5IN88US=> NY\wNndmW0GQR1XS
KE-37 Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfBfHlUUUN3ME22Ok4zPjZ6IN88US=> NV62R|k6W0GQR1XS
D-542MG MmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlqzTWM2OD14OD60NVM2KM7:TR?= NVXDfpJvW0GQR1XS
MHH-PREB-1 M3\Rb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\lUZlKSzVyPUeyMlg1PDFizszN NULqR5ZvW0GQR1XS
MRK-nu-1 M3L4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTd|LkS3NFUh|ryP NVG4VmxOW0GQR1XS
D-247MG MnPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnLfVYyUUN3ME23N{42PDR{IN88US=> Ml;SV2FPT0WU
OCI-AML2 M4C2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTd4LkmzOlkh|ryP MoTCV2FPT0WU
LP-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmf0TWM2OD16Mj64O|MyKM7:TR?= M1rPfXNCVkeHUh?=
HCC1599 NV62OYxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILUfIlKSzVyPUi0MlI5OzdizszN MoHSV2FPT0WU
KARPAS-45 MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfvcoxKSzVyPUi0MlY6QTJizszN M1\LPXNCVkeHUh?=
BE-13 MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;JWoZXUUN3ME25PU4xPDd5IN88US=> NFj0WWZUSU6JRWK=
GCIY MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWL1cYxOUUN3ME25PU4xQTV2IN88US=> MmqzV2FPT0WU
BV-173 NXr4e|d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFyMD6zNlUh|ryP MUPTRW5ITVJ?
LB2518-MEL NUjkZ5RiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTFyMD63PFkh|ryP M3nC[XNCVkeHUh?=
KS-1 M3vkSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTFyMT62N|kh|ryP NGi3R45USU6JRWK=
MOLT-16 NGnFdVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PNSGlEPTB;MUC0Mlk5PiEQvF2= MXzTRW5ITVJ?
NCI-H1770 MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7tVGVKSzVyPUGwPE44QDRizszN NIf5fnhUSU6JRWK=
NCI-H82 M1\2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvrT3RHUUN3ME2xNVAvQTd4IN88US=> Mn7IV2FPT0WU
NCCIT MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;TcWlEPTB;MUGyMlUzQSEQvF2= NGjlUoZUSU6JRWK=
KALS-1 MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\xTWM2OD1zMUWuPVQyKM7:TR?= NYDlUnlUW0GQR1XS
LB2241-RCC M1fES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTFzNj62O|kh|ryP NXTEV3ZOW0GQR1XS
HH NHnWZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33rNGlEPTB;MUG3MlM6PSEQvF2= MkXJV2FPT0WU
HD-MY-Z NGDtfItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fnWWlEPTB;MUG4MlQ5QCEQvF2= NU\vSlN1W0GQR1XS
EB-3 NGHuSY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3yyS2lEPTB;MUKzMlA6PCEQvF2= NULYXo5bW0GQR1XS
BL-70 NXO4eGpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF{Mz6xNlch|ryP M4PR[XNCVkeHUh?=
K-562 NUT5XlZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[xTWM2OD1zMk[uNlQ2KM7:TR?= NHOyVpBUSU6JRWK=
HT-144 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3JTWM2OD1zM{OuNVY1KM7:TR?= Mn[wV2FPT0WU
PF-382 NGLPO2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDyTWM2OD1zM{SuN|YyKM7:TR?= MkHzV2FPT0WU
RPMI-8226 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;R[VFKSzVyPUGzOU4xPDVizszN NVzUNHRyW0GQR1XS
NCI-H1355 M2q2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\sUY5KSzVyPUGzOU42QDdizszN MYLTRW5ITVJ?
LXF-289 NIHhRmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnqVIxoUUN3ME2xN|kvPzhzIN88US=> MX3TRW5ITVJ?
NCI-H69 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVqzbHQ6UUN3ME2xOFIvQTN{IN88US=> M1[4SXNCVkeHUh?=
SK-MEL-1 NXLwV|RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTF2Nz6xN{DPxE1? NXjDSopFW0GQR1XS
KARPAS-299 NUnMPZNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTF2OT6xNkDPxE1? MWfTRW5ITVJ?
GB-1 NEfLSppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\scJh6UUN3ME2xOFkvOzJ{IN88US=> NUDTTZZLW0GQR1XS
CMK MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXqTWM2OD1zNEmuOVE2KM7:TR?= M2\vbnNCVkeHUh?=
MPP-89 NX\tcWRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj6TWM2OD1zNU[uNFM2KM7:TR?= MXvTRW5ITVJ?
KU812 NWrU[Ic3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXtfIhKSzVyPUG2NU46ODJizszN NIS1cHFUSU6JRWK=
REH MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLXUGtKSzVyPUG2Nk4yOjVizszN M1exWnNCVkeHUh?=
NEC8 MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XUSWlEPTB;MU[1MlAzPiEQvF2= M1PjNXNCVkeHUh?=
KP-N-YS MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjBTWM2OD1zNkiuN|k2KM7:TR?= NHrPNGhUSU6JRWK=
Ramos-2G6-4C10 NYCzS|dXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2exW2lEPTB;MU[5MlkyPSEQvF2= M{L3SnNCVkeHUh?=
Becker NFjET3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDFNpBKSzVyPUG3OE4yQCEQvF2= NFfvRm1USU6JRWK=
LB647-SCLC NHvZfJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MomxTWM2OD1zN{WuPFQ2KM7:TR?= NFrmPI1USU6JRWK=
LU-139 NEXrdI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrsfmlKSzVyPUG3PE4xOTlizszN NX\TU3duW0GQR1XS
QIMR-WIL NFfwfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTF5OT62OFYh|ryP M2n3XnNCVkeHUh?=
NCI-H1395 NVrRNYZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnqOmhKUUN3ME2xO|kvQTl4IN88US=> NGexNXlUSU6JRWK=
NOMO-1 NIrwWFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4f2RmlEPTB;MUiyMlg2KM7:TR?= NEjsbnZUSU6JRWK=
GI-ME-N NE\XR29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\GUlBKSzVyPUG4O{46PjlizszN MU\TRW5ITVJ?
KMS-12-PE MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTF6OT6yO|Mh|ryP NF65WmRUSU6JRWK=
Daudi NXXxTVBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlewTWM2OD1zOUGuNVI5KM7:TR?= MorHV2FPT0WU
LB996-RCC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTF7MT62PVkh|ryP M3\ZTnNCVkeHUh?=
NCI-H2107 M{\zXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nr[GlEPTB;MUmzMlc{QSEQvF2= MljBV2FPT0WU
SK-PN-DW MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTF7ND63NVkh|ryP M4TLZXNCVkeHUh?=
MC-CAR MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTJyMj6yOVMh|ryP M{Tlc3NCVkeHUh?=
SNB75 NYrreI06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkOyTWM2OD1{MkGuPVQh|ryP Mn;RV2FPT0WU
ES4 MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnLPGlnUUN3ME2yNlMvPzh|IN88US=> M4Lz[nNCVkeHUh?=
KARPAS-422 NHrueJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmr5TWM2OD1{MkiuN|UzKM7:TR?= M{DaZnNCVkeHUh?=
NCI-H1648 NWeyd2N1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfuS3NKSzVyPUKyPU41QDlizszN M{n3VXNCVkeHUh?=
ES6 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PFXmlEPTB;MkO5MlQ{KM7:TR?= NXHObHBjW0GQR1XS
KNS-81-FD NIjQfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX6S4NyUUN3ME2yOFEvOTl5IN88US=> NVPKXIJ4W0GQR1XS
JAR MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnmTWM2OD1{NU[uNlI2KM7:TR?= M33RTnNCVkeHUh?=
NB1 M3P5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnxU4pKSzVyPUK2NE42OTZizszN NIjhd4tUSU6JRWK=
D-336MG MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PhWmlEPTB;Mk[wMlY6QCEQvF2= MlHiV2FPT0WU
BC-3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml23TWM2OD1{NkWuNVc5KM7:TR?= NX73bXFZW0GQR1XS
HCC2218 NFfTWm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTJ4Nj60NVUh|ryP NGHtV2dUSU6JRWK=
TE-9 NXTpflZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETRPYZKSzVyPUK2Ok43OjdizszN MUjTRW5ITVJ?
LB1047-RCC MlzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4P1NGlEPTB;Mk[2Mlc2OyEQvF2= M2K0bnNCVkeHUh?=
CTB-1 M2\PTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\ITWM2OD1{NkmuPVc{KM7:TR?= MVnTRW5ITVJ?
NB7 NWPPe3U6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvIV2pvUUN3ME2yO|Eh|ryP NIP4ZWNUSU6JRWK=
ST486 NXf2b|Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TUWWlEPTB;Mke3MlQyOiEQvF2= MmPkV2FPT0WU
HCC1187 NIfITYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJ6Mj64NVEh|ryP M1f3R3NCVkeHUh?=
NCI-SNU-16 MmrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTJ6ND6yOFgh|ryP NXzibFJZW0GQR1XS
COR-L279 NXLrcnprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjtRpJKSzVyPUK5NU42QDRizszN M4fGTnNCVkeHUh?=
ES8 MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJ7ND6xPFIh|ryP M4jZbnNCVkeHUh?=
U-698-M NXHTSYxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rQOWlEPTB;Mkm4MlI1OyEQvF2= NHrPZVRUSU6JRWK=
HEL MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTNyOT6xOFkh|ryP M3K2UXNCVkeHUh?=
KINGS-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnT2TWM2OD1|MUCuOlc1KM7:TR?= MnvXV2FPT0WU
KY821 M2nkOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPLPYNKSzVyPUOzOk42QTVizszN Ml[5V2FPT0WU
MZ1-PC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nMeWlEPTB;M{S1MlYyQCEQvF2= NFXFbpdUSU6JRWK=
LS-411N NWnIO2k4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnMdY1KSzVyPUO1OE43PiEQvF2= NF\uZ4hUSU6JRWK=
SIG-M5 NGrLeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrrWlJVUUN3ME2zOVkvPzh{IN88US=> MYXTRW5ITVJ?
HT NH7Re2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrKN2dKSzVyPUO2O{44OTFizszN NYO3bHU2W0GQR1XS
HC-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfzTWM2OD1|NkeuO|g4KM7:TR?= NYD0fFdQW0GQR1XS
NCI-H1694 NV2yO4JIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzmVVlRUUN3ME2zO|IvQTN2IN88US=> MXnTRW5ITVJ?
BB65-RCC NFHOTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvITWM2OD1|N{[uNlQ2KM7:TR?= NXTTPJBLW0GQR1XS
HAL-01 MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjo[lBKSzVyPUO3PU45OzhizszN MVnTRW5ITVJ?
ARH-77 NFzNNVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\JemlEPTB;M{m0MlAxQCEQvF2= NUewXol5W0GQR1XS
MZ7-mel MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTu[ZJKSzVyPUO5O{4zOzNizszN NITCXlZUSU6JRWK=
SIMA MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DDcmlEPTB;NECzMlk{OyEQvF2= NXj2d5RyW0GQR1XS
DG-75 NUHyW3JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHkTWM2OD12MUWuOlk5KM7:TR?= MnWwV2FPT0WU
HUTU-80 MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPDZ5ZWUUN3ME20NVkvOTh3IN88US=> NWDqUopCW0GQR1XS
KNS-42 NXS5O5pQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTR{NT64NVUh|ryP NXHHcpZkW0GQR1XS
SH-4 NILUWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33Nc2lEPTB;NEK3MlU3PSEQvF2= NVSxU4d1W0GQR1XS
L-540 MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoGzTWM2OD12M{GuNFMyKM7:TR?= M{XocHNCVkeHUh?=
NB10 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jNeWlEPTB;NESxMlI{PCEQvF2= MXTTRW5ITVJ?
ES1 NWD1eY05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjZdHB2UUN3ME20OVIvPzV|IN88US=> NFjrPIhUSU6JRWK=
KMOE-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFflSpZKSzVyPUS1Ok44OTFizszN NIn6TnJUSU6JRWK=
MC116 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PwRWlEPTB;NEW4MlEyPiEQvF2= NUPR[4lIW0GQR1XS
RCC10RGB NVjReZdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnGxTWM2OD12NkCuNFA2KM7:TR?= NFXU[mdUSU6JRWK=
RL95-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7sTWM2OD12NkCuNlM4KM7:TR?= M{DMN3NCVkeHUh?=
Raji M3XIcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmGyTWM2OD12NkiuNVQ{KM7:TR?= MYrTRW5ITVJ?
CAS-1 MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHjdYRKSzVyPUS3Nk4xPzNizszN M4fXS3NCVkeHUh?=
Calu-6 MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLkeJpqUUN3ME20O|UvOjZ3IN88US=> MojrV2FPT0WU
KG-1 MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L1TWlEPTB;NEe4MlQ1KM7:TR?= NUfQ[odMW0GQR1XS
LB771-HNC M4n1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTR6Mj6yN|Ih|ryP Mlv5V2FPT0WU
ACN NXzSWplNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUW0[GpyUUN3ME20PVMvPTl7IN88US=> Mn\2V2FPT0WU
KM12 MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXpTWM2OD12OU[uOVg6KM7:TR?= MWrTRW5ITVJ?

... Click to View More Cell Line Experimental Data

体内研究 Cyclopamine 每天按50 mg/kg剂量处理小鼠,持续22天,消除HUCCT1移植瘤,且没有明显副作用。[2] Cyclopamine 按1.2 mg剂量处理Panc 05.04和 L3.6sl驱动的肿瘤7天,前者诱导明显的肿瘤细胞凋亡,后者降低肿瘤质量,降低达50-60%,但是作用于BxPC3-SMOlow肿瘤没有效果。[3] Cyclopamine单独处理E3LZ10.7 和L3.6pl移植瘤,显著抑制肿瘤转移,且和 Gemcitabine联用处理,完全废除转移。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

激酶实验:

Gli-Luc实验测定Hh 信号通路末期, 即使用荧光素酶进行读数,测定Gli的转录调控。Cyclopamine 在DMSO中连续稀释用于实验,然后加到空的实验板上。TM3Hh12 细胞(TM3 细胞含Hh反应受体基因结构 pTA-8xGli-Luc) 悬浮在含5% FBS 和15 mM Hepes pH 7.3的F12 Ham’s/DMEM (1:1)培养基上, 加到实验板上,与Cyclopamine在37oC下温育30分钟左右。1 nM Hh-Ag 1.5 加到实验板上,然后在37oC下温育。48小时后,在实验板中加入Bright-Glo或MTS,然后在492 nm处测定发光度或吸光度。通过分析反应曲线,使用R统计软件包测定IC50值。
细胞实验:[2]
+ 展开
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, 和HCT116
  • Concentrations: 溶于DMSO, 终浓度为3 μM
  • Incubation Time: 4天
  • Method: 在96孔板上,用Cyclopamine 处理细胞。通过MTS实验测定细胞活力。进行CellTiter96比色测定,进行2和4天,然后在490 nm处通过测定光密度而测定存活细胞。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 皮下注射HUCCT1细胞的无胸腺裸鼠
  • Formulation: 溶于DMSO, 然后用盐水稀释
  • Dosages: 50 mg/kg/day
  • Administration: 皮下注射处理
    (Only for Reference)

溶解度 (25°C)

体外 DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 411.62
化学式

C27H41NO2

CAS号 4449-51-8
稳定性 powder
in solvent
别名 11-deoxojervine

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to reconstitute the compound for in vivo use in mice?

  • 回答:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

相关Hedgehog/Smoothened产品

Tags: 购买Cyclopamine | Cyclopamine供应商 | 采购Cyclopamine | Cyclopamine价格 | Cyclopamine生产 | 订购Cyclopamine | Cyclopamine代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID